Aethlon Medical enrolls first patient in Hemopurifier cancer trial for solid tumors

AETHLON MEDICAL INC

First patient enrolled Oct 29, 2024 at Royal Adelaide Hospital; eligibility confirmed Nov 8.
Trial is safety, feasibility, dose-finding for Hemopurifier in solid tumors not responding to anti-PD-1 antibodies.
Two-month run-in on anti-PD-1 therapy; if no tumor improvement, patient treated with Hemopurifier.
Trial targets 9-18 patients; primary endpoint is adverse events and safety lab changes.
Exploratory endpoints measure extracellular vesicle reduction and T cell activity improvement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.